Format

Send to

Choose Destination
Antivir Ther. 2017;22(4):365-368. doi: 10.3851/IMP3130. Epub 2017 Jan 13.

HCV intergenotype 2k/1b recombinant detected in a DAA-treated patient in Italy.

Author information

1
Molecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
2
Division of Infectious Diseases and Immunology, Department of Medical Sciences and Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
3
Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.
4
Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.

Abstract

Direct-acting antiviral (DAA) combinations are potent and effective drugs currently recommended for treatment of chronic HCV infection. Difficult to treat genotypes are the most important predictors of treatment failure. We report a case of DAA treatment failure in an HCV-infected patient carrying a recombinant genotype 2k/1b. This strain, first isolated from a Russian patient in 2002, has now been observed for the first time in Italy.

PMID:
28085002
DOI:
10.3851/IMP3130
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center